Pelthos Therapeutics Inc.

Greetings and welcome to the Q2 2026 Peltos Therapeutics conference call. At this time, all participants are in a listen-only mode. A question and answer session will follow the formal presentation. If anyone requires operator assistance during the conference, please press star zero on your telephone keypad. As a reminder, this conference is being recorded. I would now like to turn the conference over to your host, Mike Moyer of LifeSci Advisors. You may begin.

Good morning, everyone, and welcome to Peltos Therapeutics' 2026 Second Quarter Financial Results Conference Call. Peltos issued a press release today announcing its financial results for the quarter ended June 30, 2026. A copy can be found in the Investor Relations tab on the company's corporate website at www.peltos.com. Before we begin, I'd like to remind you that during today's call, statements about the company's future expectations, projections, plans, and prospects are forward-looking statements. These forward-looking statements are based on management's current expectations. These statements are neither promises nor guarantees and involve known and unknown risks. uncertainties and other important factors that may cause the company's actual results, performance or achievements to be materially different from the company's current expectations expressed or implied by the forward-looking statements. Any such forward-looking statements represent management's estimates as of the date of this conference call. While the company may elect to update such forward-looking statements at some point in the future, it disclaims any obligation to do so, even if subsequent events cause its views to change. As a reminder, this conference call is being recorded and will remain available for 90 days. I'd now like to turn the call over to Scott Plesha, Chief Executive Officer. Scott, you may begin.

Thank you, Mike, and good morning, everyone. We're delighted to be with you today and share with you our second quarter 2026 operating results and highlights. Joining me today are John Gay, our Chief Financial Officer, and Sai Rangarao, our Chief Commercial Officer. The second quarter of 2026 was a successful one for Peltos with a strong execution and progress made in several key areas that I'll share at a high level with you. First, we experienced substantial revenue growth driven by increased prescriptions of our lead product, Zelsudme, in this fourth quarter since launch. Next, the contracts we executed with a major pharmacy benefit manager at the end of last year has been an important catalyst in demand for Zelsudme. Within this PDM, units dispensed increased 81.3% during the quarter, while the number of prescribers increased 68%. We continue to explore additional contracting options to further our reach and market penetration. Finally, we continue to make progress in establishing the manufacturing of our two other highly complementary products, Zepi and Zeglize. John and Sai will provide a more detailed look at the quarters they'll soon be launching metrics and reported financial results, but I'd like to share a brief overview of our results of operations. Our top line results were driven by a 48% increase in prescription units as reported by Symphony Health, which increased from 8,084 units in the first quarter of 2026 to 11,925 units in the second quarter of 2026. This drove an increase in net product revenue from 10.7 million during the first quarter of 2026 to 15.4 million in the second quarter of 2026. Importantly, we achieved this growth with only a minimal increase in wholesale inventory while reducing days on hand by approximately three days from the end of Q1 2026 to the end of Q2 2026. As a reminder, Zelsubme is a novel topical nitric oxide-releasing product indicated for the treatment of molluscum contagiosum, or MC, in patients one year of age and older for up to 12 weeks. Tilsumi is an important advancement in the treatment of MC as it's the first and only FDA-approved therapy that can be applied by parents, patients, or caregivers in the home or on the go. We believe the opportunity to treat MC at home without the need for an in-office procedure has been and will continue to be a key driver of Tilsumi demand. We are pleased with the growth delivered in Q2 and are confident in our future performance. Our belief remains strong that zelsovmi is revolutionizing the treat of MC and is becoming the first-line treatment of choice for many HCPs and patients. This is supported by the recent August 2026 Journal of Drugs and Dermatology, JDD, publication titled Molluscum Contagiosum in the Pediatric Population, Expert Consensus Guidance on Prevention and Treatment, which includes Berdasmir 10.3% gel, zelsovmi, as the only at-home available treatment option for MC that can provide clinically meaningful clearance rates, and when combined with supportive management, provides an opportunity to improve outcomes and quality of life for children with MC. These landmark guidelines represent a significant advancement in the management of MC, and we're committed to ensuring they are appropriately communicated to healthcare professionals who treat MC. Regarding Zepi and Zeglyce, Zepi is a novel, FDA-approved topical treatment for empatigo that addresses a critical unmet need in antibiotic-resistant skin infections caused by staph and strep infections, most commonly affecting children. Empatigo is the most common skin infection in children seen by pediatricians, with approximately 3 million patients diagnosed with this bacterial infection each year. We believe Zepi is a highly complementary product, as it mostly treats children that are managed by the same healthcare providers as Zelsugni. Importantly, this allows us to leverage our commercial infrastructure, including our expanded sales force. We continue to focus on establishing the manufacturing process and building launch inventory, and expect to launch Zepi in the first quarter of 2027. With respect to Zeglyze, Zeglyze is a novel FDA-approved product indicated for the treatment of head lice in patients six months of age or older that is highly complementary to Zelsudone and Zepi and is expected to require minimal incremental overhead to commercialize. At the operational level, we are standing up manufacturing for Zeglyze and expect to bring it to market in the third quarter of 2027. Both Zepi and Zeglize will have meaningful call overlap for existing Salesforce, providing the company with greater operational and financial leverage from our existing team and infrastructure. In summary, we are pleased with the strong response from healthcare professionals to Zelsubme, as demonstrated by the more than 30,000 units dispensed since its launch in July of 2025. We continue to plan for the upcoming launches of Zepi and Zeglize to complementary FDA-approved products. will continue to evaluate and optimize our commercial strategy to drive sustainable long-term shareholder value. I'll now turn it over to Sai to provide more specifics on the results of the Zelsuvme launch and key performance indicators.